ALVAC-HIV (vCP2438)
AXP000203.1 · Vaccine
- Platform
- canarypox (ALVAC)
- Targets
- HIV-1 subtype C gp120; HIV-1 Gag; HIV-1 protease
- Originator
- Sanofi Pasteur
- Sponsor
- Sanofi Pasteur
Names
| Name | Type | Source |
|---|---|---|
| ALVAC-HIV (vCP2438) | preferred name | curator |
| ALVAC-HIV vCP2438 | code | paper |
| vCP2438 | code | paper |
| ALVAC-HIV (subtype C) ambiguous | synonym | press |
Virus
- Role
- Vaccine vector
- Family
- Poxviridae
- Virus
- canarypox virus (NCBI Taxonomy 44088)
- Strain
- ALVAC (vCP2438)
- Replication
- non replicating
- Modifications
- HIV-1 clade C (ZM96) env gp120 with clade B LAI gp41 anchor, plus LAI gag and protease
- Transgenes
- HIV-1 env gp120 (clade C ZM96), HIV-1 gag (LAI), HIV-1 protease (LAI)
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (4)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT03122223 | Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants | Completed | Phase 1/2 | 2018-01-16 | 2020-07-30 | 160 | HIV Infections |
| NCT03284710 | Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine | Completed | Phase 1/2 | 2017-06-19 | 2019-12-12 | 132 | HIV Infections |
| NCT02968849 | Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa | Completed | Phase 2/3 | 2016-10-26 | 2021-11-16 | 5404 | HIV Infections |
| NCT02404311 | A Safety and Immune Response Study of 2 Experimental HIV Vaccines | Completed | Phase 1/2 | 2015-02-02 | 2018-08-07 | 252 | HIV Infection |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41121745 | Large Language Models for Clinical Trial Protocol Assessments. | Clinical pharmacology and therapeutics | 2026 | cited by trial NCT02968849 |
| PMID 41909709 | AS01B-, MF59-, and alum-based adjuvants and HIV vaccine immunogenicity: a post-hoc cross-protocol comparison of results from HVTN 100, 107, 120, and 702. | Frontiers in immunology | 2026 | name in abstract: ALVAC-HIV vCP2438 |
| PMID 40190112 | A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials. | Emerging microbes & infections | 2025 | cited by trial NCT02404311 |
| PMID 37795976 | Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120. | The Journal of infectious diseases | 2024 | cited by trial NCT03122223 |
| PMID 38502656 | Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial. | PLoS medicine | 2024 | cited by trial NCT03284710 |
| PMID 38772835 | Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702. | Vaccine | 2024 | cited by trial NCT02968849 |
| PMID 39302924 | Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial. | PLOS global public health | 2024 | cited by trial NCT02404311 |
| PMID 37355583 | Data quality in an HIV vaccine efficacy clinical trial in South Africa: through natural disasters and with discipline. | BMC medical research methodology | 2023 | cited by trial NCT02968849 |
| PMID 34895272 | Participants' characteristics and motivations to screen for HIV vaccine and monoclonal antibody trials in KwaZulu-Natal, South Africa. | Trials | 2021 | cited by trial NCT02404311 |
| PMID 31999736 | Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. | PloS one | 2020 | cited by trial NCT02404311 |
| PMID 32092060 | Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. | PLoS medicine | 2020 | cited by trial NCT02404311 |
| PMID 29898870 | Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. | The lancet. HIV | 2018 | cited by trial NCT02404311 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40438096 | Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccines. | Frontiers in immunology | 2025 | name in abstract: ALVAC-HIV vCP2438 |
| PMID 30104115 | In vitro assessment of biological activity and stability of the ALVAC-HIV vaccine. | Vaccine | 2018 | name in abstract: ALVAC-HIV vCP2438 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| ZIABC012025 | Phase I HIV vaccine trial with DNAALVAC-HIV gp120 delta V1 vaccines | DIVISION OF BASIC SCIENCES - NCI | FRANCHINI, GENOVEFFA | 2025–2025 | name in abstract: vCP2438 |
| ZIABC012211 | Essential Logistic Needs to Implement the C.L.E.A.R. Phase-I HIV Vaccine Trial | DIVISION OF BASIC SCIENCES - NCI | FRANCHINI, GENOVEFFA | 2025–2025 | name in abstract: vCP2438 |
| U19AI142596 | Core-001 | DUKE UNIVERSITY | HAYNES, BARTON F. | 2019–2024 | name in abstract: vCP2438 |
Notes
Canarypox vector vCP2438, the subtype C adaptation of vCP1521: clade C ZM96 env gp120 with a clade B LAI gp41 anchor, plus LAI gag and protease. Prime in HVTN 100 and the phase 2b/3 HVTN 702 (Uhambo) trial in South Africa (5,407 participants, NIAID), with MF59-adjuvanted bivalent subtype C gp120 protein; vaccinations stopped January 2020 for no efficacy. A different construct from vCP1521, so a separate program.
How to cite
ALVAC-HIV (vCP2438) (AXP000203.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000203.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.